Last reviewed · How we verify

NCT04645173: HEAL

Comparison of Participants Who Received a CanGaroo® Envelope, TYRX™ Envelope, or no Envelope During CIED Implantation

Completed Last updated 9 January 2024
What this trial tests

trial testing CIED envelope in Cardiac Disease in 46 participants. Completed in 31 December 2023.

Timeline
2 February 2021
Primary endpoint
31 October 2023
31 December 2023

Quick facts

Lead sponsorElutia Inc.
StatusCompleted
Study typeOBSERVATIONAL
Enrollment46
Start date2 February 2021
Primary completion31 October 2023
Estimated completion31 December 2023
Sites11 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Elutia Inc.

Who can join

18 and older, any sex, with Cardiac Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to gather information on participants returning at time of CIED change-out or revision who underwent a device implantation with either a CanGaroo® envelope, TYRX™ envelope, or no envelope.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Rehabilitation of an existing device implant pocket using a biologic extracellular matrix envelope.
    Srivastava A, Nayak HM. · · 2023 · cited 4× · PMID 38023680 · DOI 10.1016/j.hrcr.2023.08.007
  2. Preclinical and clinical evaluation of ECM bioenvelopes for preventing CIED pocket complications.
    Catanzaro JN, Christopher TJ, Issa ZF, Nekkanti R, et al · · 2025 · PMID 41019442 · DOI 10.3389/fcvm.2025.1638929

Verify or expand the search:

Other recruiting trials for Cardiac Disease

Currently open trials in the same condition.

Other Elutia Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04645173.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing